無血管性壊死の世界市場レポート 2025年

無血管性壊死市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.3％で、12億7,000万米ドルに成長する見込みです。予測期間中に予想される成長は、コルチコステロイド誘発性骨壊死の発生率の増加、人工膝関節置換術や股関節手術の件数の増加、薬剤承認の急増、交通事故率の増加、骨損傷の有病率の増加などに起因しています。予測期間中に予想される主要動向には、技術革新、画像技術の進歩、AI主導の診断ソリューション、3Dプリンティング外科用インプラント、再生整形生物工学、細胞療法などが含まれます。

人工膝関節置換術や人工股関節置換術の増加は、今後数年間の無血管性壊死市場の成長を促進すると予測されます。人工膝関節置換術や人工股関節置換術は、損傷した関節を置換し、重症の無血管性壊死の痛みを緩和することを目的とした外科手術です。このような外科手術の増加は、変形性関節症の罹患率の増加によるところが大きいです。変形性関節症は、激しい関節痛や運動機能の低下を引き起こす疾患で、生活の質を高めるために外科的介入が必要となることが多いです。無血管性壊死は、血流の減少による骨組織の死滅を引き起こし、関節の崩壊や悪化を頻繁に引き起こすため、このような手術の必要性を生み出す上で重要な役割を果たしています。例えば、2023年9月、米国を拠点とするヘルスケア技術企業であるCurvo Labs, Inc.は、米国における人工膝関節置換術の件数は、2021年の123万5,835件から2022年には129万9,084件に増加したと報告しています。このように、人工膝関節置換術と人工股関節置換術の件数の増加が無血管性壊死市場の成長を促進しています。

ヘルスケア支出の増加は、今後の無血管性壊死市場の成長をサポートすると予測されています。ヘルスケア支出とは、特定の人口やヘルスケアシステムにおける医療サービス、治療、健康関連製品への総支出を指します。この支出は、継続的な管理、度重なる通院、高額な薬剤を必要とする慢性疾患の蔓延により増加しています。無血管性壊死の文脈では、ヘルスケア支出の増加は、早期診断、先進的治療オプション、外科的介入へのアクセスを容易にし、病状の管理と患者の転帰の改善を支援します。例えば、2025年4月、米国を拠点とする医師と医療生を代表する組織である米国医師会は、米国の医療費は2022年の4.6％増から2023年には7.5％増の4兆9,000億米ドル、1人当たり1万4,570米ドルになると報告しました。したがって、医療費の増加が無血管性壊死市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の無血管性壊死：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の無血管性壊死市場：成長率分析
• 世界の無血管性壊死市場の実績：規模と成長、2019～2024年
• 世界の無血管性壊死市場の予測：規模と成長、2024～2029年、2034年
• 世界の無血管性壊死：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の無血管性壊死市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 外傷性虚血性壊死
• 非外傷性虚血性壊死
• 世界の無血管性壊死市場：診断別、実績と予測、2019～2024年、2024～2029年、2034年
• 画像診断
• 生検
• コンピュータ断層撮影スキャン
• 陽電子放出断層撮影
• X線
• 世界の無血管性壊死市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 医薬品
• 手術
• 理学療法
• ライフスタイルの変化
• 骨移植
• 世界の無血管性壊死市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• リハビリテーションセンター
• 外来手術センター
• 在宅ケア
• 世界の無血管性壊死市場、外傷性虚血性壊死のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 骨折誘発性無血管性壊死
• 転位誘発性無血管性壊死
• 術後無血管性壊死
• 圧迫損傷関連の無血管性壊死
• スポーツ傷害関連無血管性壊死
• 世界の無血管性壊死市場、非外傷性虚血性壊死のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ステロイド誘発性無血管性壊死
• アルコール誘発性無血管性壊死
• 鎌状赤血球症関連無血管性壊死
• ループス関連無血管性壊死
• 放射線療法誘発性無血管性壊死
• 特発性無血管性壊死

第7章 地域別・国別分析

• 世界の無血管性壊死市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の無血管性壊死市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 無血管性壊死市場：競合情勢
• 無血管性壊死市場：企業プロファイル
  • Stryker Corporation
  • Massachusetts General Hospital
  • Zimmer Biomet Holdings Inc.
  • Smith & Nephew plc
  • Stanford Health Care

第31章 その他の大手企業と革新的企業

• Apollo Hospitals Enterprise Limited
• Singapore General Hospital Pte Ltd.
• Fortis Healthcare Limited
• Narayana Hrudayalaya Limited
• Bumrungrad International Hospital Co. Ltd.
• Aster DM Healthcare Limited
• Mount Elizabeth Hospital Pte Ltd.
• Gleneagles Hospital Pte Ltd.
• Shalby Limited
• Texas Orthopedic Hospital LLC
• Regrow Biosciences Pvt. Ltd.
• Maxcure Hospitals Limited
• Medicover Hospitals Private Limited
• Mesoblast Limited
• Athersys Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 無血管性壊死市場、2029年：新たな機会を提供する国
• 無血管性壊死市場、2029年：新たな機会を提供するセグメント
• 無血管性壊死市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Avascular necrosis (AVN) is a condition characterized by the death of bone tissue due to an insufficient blood supply. When blood flow to a bone is reduced or interrupted, bone cells begin to deteriorate, ultimately leading to the collapse of the bone structure and potential joint damage. The condition may arise from factors such as physical trauma, prolonged steroid use, excessive alcohol intake, or certain underlying medical conditions.

Avascular necrosis is primarily classified into trauma-related and non-trauma-related avascular necrosis. Trauma-related AVN develops following bone injuries like fractures or joint dislocations, which obstruct blood circulation and lead to bone tissue death. Diagnosis methods for AVN include imaging techniques, biopsies, computed tomography (CT) scans, positron emission tomography (PET), and X-rays. Treatment options range from medication and surgery to physical therapy, lifestyle modifications, and bone grafting. The condition is managed across various healthcare settings, including hospitals, specialty clinics, rehabilitation centers, ambulatory surgical centers, and home care environments.

The avascular necrosis market research report is one of a series of new reports from The Business Research Company that provides avascular necrosis market statistics, including avascular necrosis industry global market size, regional shares, competitors with an avascular necrosis market share, detailed avascular necrosis market segments, market trends and opportunities, and any further data you may need to thrive in the avascular necrosis industry. This avascular necrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The avascular necrosis market size has grown strongly in recent years. It will grow from $0.81 billion in 2024 to $0.89 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historic period can be attributed to several factors, including the increasing aging population, rising levels of alcohol consumption, expansion of sports medicine, growth in medical tourism, and advancements in precision medicine.

The avascular necrosis market size is expected to see strong growth in the next few years. It will grow to $1.27 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth during the forecast period can be credited to the increasing incidence of corticosteroid-induced osteonecrosis, a rising number of knee replacements and hip surgeries, a surge in drug approvals, a higher rate of road accidents, and a growing prevalence of bone injuries. Key trends expected in the forecast period include technological innovations, advancements in imaging technologies, AI-driven diagnostic solutions, 3D-printed surgical implants, regenerative orthobiologics, and cellular therapies.

The increasing number of knee and hip replacement surgeries is anticipated to drive the growth of the avascular necrosis market in the coming years. Knee and hip replacements are surgical procedures aimed at replacing damaged joints and alleviating pain in severe cases of avascular necrosis. This rise in surgical procedures is largely due to the growing incidence of osteoarthritis, a condition that leads to intense joint pain and impaired mobility, often necessitating surgical intervention to enhance quality of life. Avascular necrosis plays a significant role in creating the need for such surgeries, as it causes the death of bone tissue from reduced blood flow, which frequently results in joint collapse and deterioration. For example, in September 2023, Curvo Labs, Inc., a U.S.-based healthcare technology firm, reported that knee replacement procedures in the U.S. rose from 1,235,835 in 2021 to 1,299,084 in 2022. Thus, the rising number of knee and hip replacements is fueling the growth of the avascular necrosis market.

The increasing healthcare expenditure is projected to support the growth of the avascular necrosis market in the future. Healthcare expenditure refers to the total spending on medical services, treatments, and health-related products within a given population or healthcare system. This expenditure is rising due to the growing prevalence of chronic illnesses, which demand ongoing management, repeated hospital visits, and expensive medications. In the context of avascular necrosis, higher healthcare spending facilitates access to early diagnosis, advanced therapeutic options, and surgical interventions that aid in managing the condition and improving patient outcomes. For example, in April 2025, the American Medical Association, a U.S.-based organization representing physicians and medical students, reported that health spending in the U.S. rose by 7.5% in 2023 to $4.9 trillion, or $14,570 per person, up from a 4.6% increase in 2022. Hence, the rise in healthcare expenditure is contributing to the growth of the avascular necrosis market.

Leading companies in the avascular necrosis market are securing regulatory approvals to broaden their product offerings, improve treatment alternatives, and reinforce their market position. Regulatory approvals are official authorizations granted by health authorities, allowing a medical product or therapy to be marketed and used after demonstrating compliance with safety and efficacy standards. For example, in May 2022, Regrow Biosciences, a biotechnology company based in India, received approval from the United States Food and Drug Administration to initiate Phase II clinical trials in the U.S. for OSSGROW, an orphan drug intended for the treatment of osteonecrosis (avascular necrosis). OSSGROW is an innovative, patient-specific bone cell therapy developed by Regrow Biosciences for the curative treatment of early to moderate stages (up to Stage III) of avascular necrosis. The treatment involves collecting the patient's bone marrow, isolating mesenchymal stem cells, and culturing them in a specialized lab to generate osteoblasts-cells responsible for forming bone. OSSGROW is regarded as a natural, safe, and potentially long-term solution designed to replace conventional therapies and joint replacement surgeries that only alleviate symptoms.

Major players in the avascular necrosis market are Stryker Corporation, Massachusetts General Hospital, Zimmer Biomet Holdings Inc., Smith & Nephew plc, Stanford Health Care, Apollo Hospitals Enterprise Limited, Singapore General Hospital Pte Ltd., Fortis Healthcare Limited, Narayana Hrudayalaya Limited, Bumrungrad International Hospital Co. Ltd., Aster DM Healthcare Limited, Mount Elizabeth Hospital Pte Ltd., Gleneagles Hospital Pte Ltd., Shalby Limited, Texas Orthopedic Hospital LLC, Regrow Biosciences Pvt. Ltd., Maxcure Hospitals Limited, Medicover Hospitals Private Limited, Mesoblast Limited, Athersys Inc., Ginger Healthcare Private Limited.

North America was the largest region in the avascular necrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in avascular necrosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the avascular necrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The avascular necrosis market consists of revenues earned by entities by providing services such as radiology services, pharmacotherapy management services, long-term preventive treatment, and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The avascular necrosis market also includes sales of products, including bone graft materials, orthopedic implants, C1 esterase inhibitors, and platelet-rich plasma kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Avascular Necrosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on avascular necrosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for avascular necrosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The avascular necrosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Trauma Related Avascular Necrosis; Non-Trauma Related Avascular Necrosis
• 2) By Diagnosis: Imaging; Biopsy; Computed Tomography Scan; Positron Emission Tomography; X-Ray
• 3) By Treatment Type: Medications; Surgery; Physical Therapy; Lifestyle Changes; Bone Grafting
• 4) By End-User: Hospitals; Specialty Clinics; Rehabilitation Centers; Ambulatory Surgical Centers; Home Care Settings
• Subsegment:
• 1) By Trauma-Related Avascular Necrosis: Fracture-Induced Avascular Necrosis; Dislocation-Induced Avascular Necrosis; Post-Surgical Avascular Necrosis; Crush Injury-Related Avascular Necrosis; Sports Injury-Associated Avascular Necrosis
• 2) By Non-Trauma Related Avascular Necrosis: Steroid-Induced Avascular Necrosis; Alcohol-Induced Avascular Necrosis; Sickle Cell Disease-Associated Avascular Necrosis; Lupus-Related Avascular Necrosis; Radiation Therapy-Induced Avascular Necrosis; Idiopathic Avascular Necrosis
• Companies Mentioned: Stryker Corporation; Massachusetts General Hospital; Zimmer Biomet Holdings Inc.; Smith & Nephew plc; Stanford Health Care
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Avascular Necrosis Market Characteristics

3. Avascular Necrosis Market Trends And Strategies

4. Avascular Necrosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Avascular Necrosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Avascular Necrosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Avascular Necrosis Market Growth Rate Analysis
• 5.4. Global Avascular Necrosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Avascular Necrosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Avascular Necrosis Total Addressable Market (TAM)

6. Avascular Necrosis Market Segmentation

• 6.1. Global Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trauma Related Avascular Necrosis
• Non-Trauma Related Avascular Necrosis
• 6.2. Global Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging
• Biopsy
• Computed Tomography Scan
• Positron Emission Tomography
• X-Ray
• 6.3. Global Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Surgery
• Physical Therapy
• Lifestyle Changes
• Bone Grafting
• 6.4. Global Avascular Necrosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Rehabilitation Centers
• Ambulatory Surgical Centers
• Home Care Settings
• 6.5. Global Avascular Necrosis Market, Sub-Segmentation Of Trauma Related Avascular Necrosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fracture-Induced Avascular Necrosis
• Dislocation-Induced Avascular Necrosis
• Post-Surgical Avascular Necrosis
• Crush Injury-Related Avascular Necrosis
• Sports Injury-Associated Avascular Necrosis
• 6.6. Global Avascular Necrosis Market, Sub-Segmentation Of Non-Trauma Related Avascular Necrosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Steroid-Induced Avascular Necrosis
• Alcohol-Induced Avascular Necrosis
• Sickle Cell Disease-Associated Avascular Necrosis
• Lupus-Related Avascular Necrosis
• Radiation Therapy-Induced Avascular Necrosis
• Idiopathic Avascular Necrosis

7. Avascular Necrosis Market Regional And Country Analysis

• 7.1. Global Avascular Necrosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Avascular Necrosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Avascular Necrosis Market

• 8.1. Asia-Pacific Avascular Necrosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Avascular Necrosis Market

• 9.1. China Avascular Necrosis Market Overview
• 9.2. China Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Avascular Necrosis Market

• 10.1. India Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Avascular Necrosis Market

• 11.1. Japan Avascular Necrosis Market Overview
• 11.2. Japan Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Avascular Necrosis Market

• 12.1. Australia Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Avascular Necrosis Market

• 13.1. Indonesia Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Avascular Necrosis Market

• 14.1. South Korea Avascular Necrosis Market Overview
• 14.2. South Korea Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Avascular Necrosis Market

• 15.1. Western Europe Avascular Necrosis Market Overview
• 15.2. Western Europe Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Avascular Necrosis Market

• 16.1. UK Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Avascular Necrosis Market

• 17.1. Germany Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Avascular Necrosis Market

• 18.1. France Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Avascular Necrosis Market

• 19.1. Italy Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Avascular Necrosis Market

• 20.1. Spain Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Avascular Necrosis Market

• 21.1. Eastern Europe Avascular Necrosis Market Overview
• 21.2. Eastern Europe Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Avascular Necrosis Market

• 22.1. Russia Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Avascular Necrosis Market

• 23.1. North America Avascular Necrosis Market Overview
• 23.2. North America Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Avascular Necrosis Market

• 24.1. USA Avascular Necrosis Market Overview
• 24.2. USA Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Avascular Necrosis Market

• 25.1. Canada Avascular Necrosis Market Overview
• 25.2. Canada Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Avascular Necrosis Market

• 26.1. South America Avascular Necrosis Market Overview
• 26.2. South America Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Avascular Necrosis Market

• 27.1. Brazil Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Avascular Necrosis Market

• 28.1. Middle East Avascular Necrosis Market Overview
• 28.2. Middle East Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Avascular Necrosis Market

• 29.1. Africa Avascular Necrosis Market Overview
• 29.2. Africa Avascular Necrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Avascular Necrosis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Avascular Necrosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Avascular Necrosis Market Competitive Landscape And Company Profiles

• 30.1. Avascular Necrosis Market Competitive Landscape
• 30.2. Avascular Necrosis Market Company Profiles
  • 30.2.1. Stryker Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Massachusetts General Hospital Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Zimmer Biomet Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Smith & Nephew plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Stanford Health Care Overview, Products and Services, Strategy and Financial Analysis

31. Avascular Necrosis Market Other Major And Innovative Companies

• 31.1. Apollo Hospitals Enterprise Limited
• 31.2. Singapore General Hospital Pte Ltd.
• 31.3. Fortis Healthcare Limited
• 31.4. Narayana Hrudayalaya Limited
• 31.5. Bumrungrad International Hospital Co. Ltd.
• 31.6. Aster DM Healthcare Limited
• 31.7. Mount Elizabeth Hospital Pte Ltd.
• 31.8. Gleneagles Hospital Pte Ltd.
• 31.9. Shalby Limited
• 31.10. Texas Orthopedic Hospital LLC
• 31.11. Regrow Biosciences Pvt. Ltd.
• 31.12. Maxcure Hospitals Limited
• 31.13. Medicover Hospitals Private Limited
• 31.14. Mesoblast Limited
• 31.15. Athersys Inc.

32. Global Avascular Necrosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Avascular Necrosis Market

34. Recent Developments In The Avascular Necrosis Market

35. Avascular Necrosis Market High Potential Countries, Segments and Strategies

• 35.1 Avascular Necrosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Avascular Necrosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Avascular Necrosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer